NovoCure Management

Management criteria checks 2/4

NovoCure's CEO is Asaf Danziger, appointed in Jan 2002, has a tenure of 22.33 years. total yearly compensation is $2.28M, comprised of 36.4% salary and 63.6% bonuses, including company stock and options. directly owns 0.013% of the company’s shares, worth €166.13K. The average tenure of the management team and the board of directors is 3.7 years and 6.5 years respectively.

Key information

Asaf Danziger

Chief executive officer

US$2.3m

Total compensation

CEO salary percentage	36.4%
CEO tenure	22.3yrs
CEO ownership	0.01%
Management average tenure	3.7yrs
Board average tenure	6.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Asaf Danziger's remuneration changed compared to NovoCure's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$207m
Sep 30 2023	n/a	n/a	-US$197m
Jun 30 2023	n/a	n/a	-US$174m
Mar 31 2023	n/a	n/a	-US$141m
Dec 31 2022	US$2m	US$831k	-US$93m
Sep 30 2022	n/a	n/a	-US$82m
Jun 30 2022	n/a	n/a	-US$68m
Mar 31 2022	n/a	n/a	-US$59m
Dec 31 2021	US$1m	US$876k	-US$58m
Sep 30 2021	n/a	n/a	-US$27m
Jun 30 2021	n/a	n/a	-US$5m
Mar 31 2021	n/a	n/a	US$12m
Dec 31 2020	US$9m	US$782k	US$20m
Sep 30 2020	n/a	n/a	US$19m
Jun 30 2020	n/a	n/a	US$12m
Mar 31 2020	n/a	n/a	US$9m
Dec 31 2019	US$7m	US$702k	-US$7m
Sep 30 2019	n/a	n/a	-US$27m
Jun 30 2019	n/a	n/a	-US$41m
Mar 31 2019	n/a	n/a	-US$55m
Dec 31 2018	US$5m	US$693k	-US$64m
Sep 30 2018	n/a	n/a	-US$59m
Jun 30 2018	n/a	n/a	-US$59m
Mar 31 2018	n/a	n/a	-US$64m
Dec 31 2017	US$4m	US$698k	-US$62m

Compensation vs Market: Asaf's total compensation ($USD2.28M) is above average for companies of similar size in the German market ($USD1.61M).

Compensation vs Earnings: Asaf's compensation has increased whilst the company is unprofitable.

CEO

Asaf Danziger (57 yo)

22.3yrs

Tenure

US$2,278,951

Compensation

Mr. Asaf Danziger is a Director at Airway Therapeutics, Inc. since April 2020. He has been the Chief Executive Officer of Novocure Limited since 2002 and its Director since 2012 respectively and also serve...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
William Doyle	Executive Chairman	20.3yrs	US$2.15m	0.51% $ 6.6m
Asaf Danziger	CEO & Director	22.3yrs	US$2.28m	0.013% $ 166.5k
Ashley Cordova	Chief Financial Officer	3.7yrs	US$6.84m	0.083% $ 1.1m
Wilhelmus C. Groenhuysen	Chief Operating Officer	3.7yrs	US$6.62m	0.17% $ 2.2m
Frank Leonard	Executive VP & President of Novocure Oncology	3.7yrs	US$6.13m	0.052% $ 661.5k
Yoram Palti	Founder & CTO	24.3yrs	US$282.51k	no data
Moshe Giladi	Chief Science Officer	1.3yrs	no data	0.0065% $ 83.4k
Ingrid Goldberg	VP of Investor Relations	no data	no data	no data
Barak Arye	General Counsel	2.1yrs	no data	0.019% $ 239.7k
Michael Puri	Chief Human Resources Officer	less than a year	no data	no data
Uri Weinberg	Chief Innovation Officer	1.3yrs	no data	0.058% $ 736.6k
Piet Hinoul	Senior VP	no data	no data	no data

3.7yrs

Average Tenure

54yo

Average Age

Experienced Management: 038's management team is considered experienced (3.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
William Doyle	Executive Chairman	20.3yrs	US$2.15m	0.51% $ 6.6m
Asaf Danziger	CEO & Director	12.3yrs	US$2.28m	0.013% $ 166.5k
Jeryl Hilleman	Independent Director	5.8yrs	US$445.20k	0.0024% $ 30.2k
David Hung	Independent Director	6yrs	US$425.09k	0.0085% $ 108.8k
Timothy Scannell	Independent Director	3.3yrs	US$439.44k	0.000070% $ 896.7
Kinyip Leung	Independent Director	12.6yrs	US$432.70k	0.070% $ 896.2k
William Vernon	Lead Independent Director	18.3yrs	US$481.54k	0.15% $ 1.9m
Martin Madden	Independent Director	7yrs	US$446.26k	0.015% $ 186.0k
Kristin Stafford	Independent Director	1.2yrs	no data	0% $ 0
Allyson Ocean	Independent Director	1.3yrs	no data	0% $ 0

6.5yrs

Average Tenure

61yo

Average Age

Experienced Board: 038's board of directors are considered experienced (6.5 years average tenure).

NovoCure Management

Management criteria checks 2/4

Key information

Recent management updates

NovoCure Limited, Annual General Meeting, Jun 05, 2024

NovoCure Limited Announces Executive Changes

Chief Operating Officer recently sold €155k worth of stock

Novocure Announces Executive Changes

Insufficient new directors

Chief Financial Officer recently sold €70k worth of stock

Recent updates

First quarter 2024 earnings released: US$0.36 loss per share (vs US$0.50 loss in 1Q 2023)

Now 24% overvalued

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

New minor risk - Shareholder dilution

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

Now 20% overvalued after recent price rise

Full year 2023 earnings released: US$1.95 loss per share (vs US$0.88 loss in FY 2022)

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma

NovoCure Limited Announces Executive Changes

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability

Third quarter 2023 earnings released: US$0.46 loss per share (vs US$0.25 loss in 3Q 2022)

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD)

Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.54 loss per share (vs US$0.23 loss in 2Q 2022)

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023

Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

First quarter 2023 earnings released: US$0.50 loss per share (vs US$0.045 loss in 1Q 2022)

Chief Operating Officer recently sold €155k worth of stock

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.56 loss in FY 2021)

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

Novocure Announces Executive Changes

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Insufficient new directors

Third quarter 2022 earnings released: US$0.25 loss per share (vs US$0.13 loss in 3Q 2021)

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting

NovoCure Limited to Report Q3, 2022 Results on Oct 27, 2022

Chief Financial Officer recently sold €70k worth of stock

Executive Chairman recently sold €57k worth of stock

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.14 loss in 2Q 2021)

NovoCure Limited to Report Q2, 2022 Results on Jul 28, 2022

Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Chief Medical Officer recently sold €252k worth of stock

First quarter 2022 earnings released: US$0.045 loss per share (vs US$0.04 loss in 1Q 2021)

Insufficient new directors

NovoCure Limited, Annual General Meeting, Jun 08, 2022

NovoCure Limited to Report Q1, 2022 Results on Apr 28, 2022

General Counsel recently sold €202k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Novocure Announces Resignation of Todd Longsworth as General Counsel

President recently bought €450k worth of stock

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$0.092 profit in 3Q 2020)

FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer

Key Executive recently sold €96k worth of stock

Key Executive recently sold €713k worth of stock

Executive Chairman recently sold €125k worth of stock

Insufficient new directors

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.016 profit in 2Q 2020)

Novocure Presents Final Safety and Efficacy Results from Its Phase 2 Pilot HEPANOVA Trial in Liver Cancer

NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 2500 Growth Index

NovoCure Limited Initiates Usability Study for Flexible Torso Array

Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer

Chief Medical Officer recently sold €335k worth of stock

First quarter 2021 earnings released: US$0.04 loss per share (vs US$0.04 profit in 1Q 2020)

Chief Commercial Officer recently sold €304k worth of stock

New 90-day low: €114

Full year 2020 earnings released: EPS US$0.20 (vs US$0.074 loss in FY 2019)

Revenue beats expectations

Novocure Appoints Timothy J. Scannell to the Board

New 90-day high: €153

NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 2000 Dynamic Index